메뉴 건너뛰기




Volumn 134, Issue 5, 2014, Pages 1055-1066

Loss of PPARγ expression in mammary secretory epithelial cells creates a pro-breast tumorigenic environment

Author keywords

breast cancer; chemical carcinogenesis; chemotherapy; knockout mouse model; mammary secretory epithelial cells; PPAR

Indexed keywords

CYCLIN D1; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIMETHYLBENZ[A]ANTHRACENE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTAGLANDIN E;

EID: 84890560335     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28432     Document Type: Article
Times cited : (37)

References (47)
  • 1
    • 0003964363 scopus 로고    scopus 로고
    • American-Cancer-Society. Atlanta: American Cancer Society
    • American-Cancer-Society. Cancer Facts & Figures, vol. 2012 Atlanta: American Cancer Society, 2012.
    • (2012) Cancer Facts & Figures , vol.2012
  • 2
    • 84890560863 scopus 로고    scopus 로고
    • Canadian-Cancer-Society. Toronto, ON: Canadian Cancer Society
    • Canadian-Cancer-Society. Canadian Cancer Statistics, vol. 2012 Toronto, ON: Canadian Cancer Society, 2012.
    • (2012) Canadian Cancer Statistics , vol.2012
  • 3
    • 0028228254 scopus 로고
    • Transient increase in the risk of breast cancer after giving birth
    • Lambe M, Hsieh C, Trichopoulos D, et al. Transient increase in the risk of breast cancer after giving birth. N Engl J Med 1994; 331: 5-9.
    • (1994) N Engl J Med , vol.331 , pp. 5-9
    • Lambe, M.1    Hsieh, C.2    Trichopoulos, D.3
  • 4
    • 28944446431 scopus 로고    scopus 로고
    • The many faces of PPARγamma
    • Lehrke M, Lazar MA,. The many faces of PPARγamma. Cell 2005; 123: 993-9.
    • (2005) Cell , vol.123 , pp. 993-999
    • Lehrke, M.1    Lazar, M.A.2
  • 5
    • 45249097593 scopus 로고    scopus 로고
    • A role for the PPARγamma in cancer therapy
    • Campbell MJ, Carlberg C, Koeffler HP,. A role for the PPARγamma in cancer therapy. PPAR Res 2008; 2008: 314974.
    • (2008) PPAR Res , vol.2008 , pp. 314974
    • Campbell, M.J.1    Carlberg, C.2    Koeffler, H.P.3
  • 6
    • 34547603895 scopus 로고    scopus 로고
    • PPARs and molecular mechanisms of transrepression
    • Ricote M, Glass CK,. PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 2007; 1771: 926-35.
    • (2007) Biochim Biophys Acta , vol.1771 , pp. 926-935
    • Ricote, M.1    Glass, C.K.2
  • 7
    • 0031898610 scopus 로고    scopus 로고
    • PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor
    • Spiegelman BM,. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-14.
    • (1998) Diabetes , vol.47 , pp. 507-514
    • Spiegelman, B.M.1
  • 8
    • 0034861516 scopus 로고    scopus 로고
    • A review of rosiglitazone in type 2 diabetes mellitus
    • Werner AL, Travaglini MT,. A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 2001; 21: 1082-99.
    • (2001) Pharmacotherapy , vol.21 , pp. 1082-1099
    • Werner, A.L.1    Travaglini, M.T.2
  • 9
    • 0030047806 scopus 로고    scopus 로고
    • Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat
    • Braissant O, Foufelle F, Scotto C, et al. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996; 137: 354-66.
    • (1996) Endocrinology , vol.137 , pp. 354-366
    • Braissant, O.1    Foufelle, F.2    Scotto, C.3
  • 10
    • 0031830264 scopus 로고    scopus 로고
    • Differential expression of the peroxisome proliferator-activated receptor gamma (PPARγamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse
    • Jain S, Pulikuri S, Zhu Y, et al. Differential expression of the peroxisome proliferator-activated receptor gamma (PPARγamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am J Pathol 1998; 153: 349-54.
    • (1998) Am J Pathol , vol.153 , pp. 349-354
    • Jain, S.1    Pulikuri, S.2    Zhu, Y.3
  • 11
    • 0031993322 scopus 로고    scopus 로고
    • Terminal differentiation of human breast cancer through PPAR gamma
    • Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998; 1: 465-70.
    • (1998) Mol Cell , vol.1 , pp. 465-470
    • Mueller, E.1    Sarraf, P.2    Tontonoz, P.3
  • 12
    • 0032555196 scopus 로고    scopus 로고
    • Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
    • Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998; 95: 8806-11.
    • (1998) Proc Natl Acad Sci U S A , vol.95 , pp. 8806-8811
    • Elstner, E.1    Muller, C.2    Koshizuka, K.3
  • 13
    • 47349108152 scopus 로고    scopus 로고
    • Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARγamma) ligand
    • Yu HN, Lee YR, Noh EM, et al. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARγamma) ligand. Cell Biol Int 2008; 32: 906-12.
    • (2008) Cell Biol Int , vol.32 , pp. 906-912
    • Yu, H.N.1    Lee, Y.R.2    Noh, E.M.3
  • 14
    • 0033571433 scopus 로고    scopus 로고
    • A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis
    • Suh N, Wang Y, Williams CR, et al. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 1999; 59: 5671-3.
    • (1999) Cancer Res , vol.59 , pp. 5671-5673
    • Suh, N.1    Wang, Y.2    Williams, C.R.3
  • 15
    • 0035002199 scopus 로고    scopus 로고
    • Therapeutic treatment of DMBA-induced mammary tumors with PPAR ligands
    • Pighetti GM, Novosad W, Nicholson C, et al. Therapeutic treatment of DMBA-induced mammary tumors with PPAR ligands. Anticancer Res 2001; 21: 825-9.
    • (2001) Anticancer Res , vol.21 , pp. 825-829
    • Pighetti, G.M.1    Novosad, W.2    Nicholson, C.3
  • 16
    • 4143150044 scopus 로고    scopus 로고
    • PPARγamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis
    • Nicol CJ, Yoon M, Ward JM, et al. PPARγamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis 2004; 25: 1747-55.
    • (2004) Carcinogenesis , vol.25 , pp. 1747-1755
    • Nicol, C.J.1    Yoon, M.2    Ward, J.M.3
  • 17
    • 58349086542 scopus 로고    scopus 로고
    • Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification
    • Yin Y, Yuan H, Zeng X, et al. Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification. Cancer Res 2009; 69: 687-94.
    • (2009) Cancer Res , vol.69 , pp. 687-694
    • Yin, Y.1    Yuan, H.2    Zeng, X.3
  • 18
    • 84865171803 scopus 로고    scopus 로고
    • Stromal adipocyte PPARγamma protects against breast tumorigenesis
    • Skelhorne-Gross G, Reid AL, Apostoli AJ, et al. Stromal adipocyte PPARγamma protects against breast tumorigenesis. Carcinogenesis 2012; 33: 1412-20.
    • (2012) Carcinogenesis , vol.33 , pp. 1412-1420
    • Skelhorne-Gross, G.1    Reid, A.L.2    Apostoli, A.J.3
  • 20
    • 10044251948 scopus 로고    scopus 로고
    • Reversible transdifferentiation of secretory epithelial cells into adipocytes in the mammary gland
    • Morroni M, Giordano A, Zingaretti MC, et al. Reversible transdifferentiation of secretory epithelial cells into adipocytes in the mammary gland. Proc Natl Acad Sci U S A 2004; 101: 16801-6.
    • (2004) Proc Natl Acad Sci U S A , vol.101 , pp. 16801-16806
    • Morroni, M.1    Giordano, A.2    Zingaretti, M.C.3
  • 21
    • 0035851187 scopus 로고    scopus 로고
    • PPARγamma: A nuclear regulator of metabolism, differentiation, and cell growth
    • Rosen ED, Spiegelman BM,. PPARγamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001; 276: 37731-4.
    • (2001) J Biol Chem , vol.276 , pp. 37731-37734
    • Rosen, E.D.1    Spiegelman, B.M.2
  • 22
    • 0030658840 scopus 로고    scopus 로고
    • Cre-mediated gene deletion in the mammary gland
    • Wagner KU, Wall RJ, St-Onge L, et al. Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res 1997; 25: 4323-30.
    • (1997) Nucleic Acids Res , vol.25 , pp. 4323-4330
    • Wagner, K.U.1    Wall, R.J.2    St-Onge, L.3
  • 23
    • 84862630475 scopus 로고    scopus 로고
    • NetWalker: A contextual network analysis tool for functional genomics
    • Komurov K, Dursun S, Erdin S, et al. NetWalker: a contextual network analysis tool for functional genomics. BMC Genomics 2012; 13: 282.
    • (2012) BMC Genomics , vol.13 , pp. 282
    • Komurov, K.1    Dursun, S.2    Erdin, S.3
  • 24
    • 0037124098 scopus 로고    scopus 로고
    • Loss of the peroxisome proliferation-activated receptor gamma (PPARγamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility
    • Cui Y, Miyoshi K, Claudio E, et al. Loss of the peroxisome proliferation-activated receptor gamma (PPARγamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem 2002; 277: 17830-5.
    • (2002) J Biol Chem , vol.277 , pp. 17830-17835
    • Cui, Y.1    Miyoshi, K.2    Claudio, E.3
  • 25
    • 0036205326 scopus 로고    scopus 로고
    • Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux
    • Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, Lee YH, Ricote M, Glass CK, Brewer HB, Jr., Gonzalez FJ,. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 2002; 22: 2607-19.
    • (2002) Mol Cell Biol , vol.22 , pp. 2607-2619
    • Akiyama, T.E.1    Sakai, S.2    Lambert, G.3    Nicol, C.J.4    Matsusue, K.5    Pimprale, S.6    Lee, Y.H.7    Ricote, M.8    Glass, C.K.9    Brewer Jr., H.10    Gonzalez, F.J.11
  • 26
    • 0141446024 scopus 로고    scopus 로고
    • Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass
    • Gavrilova O, Haluzik M, Matsusue K, et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 2003; 278: 34268-76.
    • (2003) J Biol Chem , vol.278 , pp. 34268-34276
    • Gavrilova, O.1    Haluzik, M.2    Matsusue, K.3
  • 27
    • 17044430286 scopus 로고    scopus 로고
    • PPARγamma in endothelial cells influences high fat diet-induced hypertension
    • Nicol CJ, Adachi M, Akiyama TE, et al. PPARγamma in endothelial cells influences high fat diet-induced hypertension. Am J Hypertens 2005; 18: 549-56.
    • (2005) Am J Hypertens , vol.18 , pp. 549-556
    • Nicol, C.J.1    Adachi, M.2    Akiyama, T.E.3
  • 28
    • 33747177047 scopus 로고    scopus 로고
    • Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes
    • Rosak C, Standl E, Reblin T, et al. Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes. Int J Clin Pract 2006; 60: 1040-7.
    • (2006) Int J Clin Pract , vol.60 , pp. 1040-1047
    • Rosak, C.1    Standl, E.2    Reblin, T.3
  • 29
    • 33748748206 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial
    • Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-105.
    • (2006) Lancet , vol.368 , pp. 1096-1105
    • Gerstein, H.C.1    Yusuf, S.2    Bosch, J.3
  • 30
    • 34547618810 scopus 로고    scopus 로고
    • Maternal PPAR gamma protects nursing neonates by suppressing the production of inflammatory milk
    • Wan Y, Saghatelian A, Chong LW, et al. Maternal PPAR gamma protects nursing neonates by suppressing the production of inflammatory milk. Genes Dev 2007; 21: 1895-908.
    • (2007) Genes Dev , vol.21 , pp. 1895-1908
    • Wan, Y.1    Saghatelian, A.2    Chong, L.W.3
  • 31
    • 78349256721 scopus 로고    scopus 로고
    • The role of the microenvironment in mammary gland development and cancer
    • Polyak K, Kalluri R,. The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol 2010; 2: a003244.
    • (2010) Cold Spring Harb Perspect Biol , vol.2
    • Polyak, K.1    Kalluri, R.2
  • 32
    • 84864925226 scopus 로고    scopus 로고
    • The key to unlocking the chemotherapeutic potential of PPARγamma ligands: Having the right combination
    • Skelhorne-Gross G, Nicol CJ,. The key to unlocking the chemotherapeutic potential of PPARγamma ligands: having the right combination. PPAR Res 2012; 2012: 946943.
    • (2012) PPAR Res , vol.2012 , pp. 946943
    • Skelhorne-Gross, G.1    Nicol, C.J.2
  • 33
    • 74949111637 scopus 로고    scopus 로고
    • Targeting CCL11 in the treatment of ovarian cancer
    • Nolen BM, Lokshin AE,. Targeting CCL11 in the treatment of ovarian cancer. Exp Opin Ther Tar 2010; 14: 157-67.
    • (2010) Exp Opin Ther Tar , vol.14 , pp. 157-167
    • Nolen, B.M.1    Lokshin, A.E.2
  • 34
    • 84878802497 scopus 로고    scopus 로고
    • CCL5 as a potential immunotherapeutic target in triple-negative breast cancer
    • Lv D, Zhang Y, Kim HJ, Zhang L, Ma X,. CCL5 as a potential immunotherapeutic target in triple-negative breast cancer. Cellular & molecular immunology 2013; 10: 303-10.
    • (2013) Cellular & Molecular Immunology , vol.10 , pp. 303-310
    • Lv, D.1    Zhang, Y.2    Kim, H.J.3    Zhang, L.4    Ma, X.5
  • 35
    • 84883890972 scopus 로고    scopus 로고
    • Oxidative stress and lipid peroxidation products in cancer progression and therapy
    • Barrera G,. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol 2012; 2012: 137289.
    • (2012) ISRN Oncol , vol.2012 , pp. 137289
    • Barrera, G.1
  • 36
    • 15444371092 scopus 로고    scopus 로고
    • Nicotine inactivation of the proapoptotic function of Bax through phosphorylation
    • Xin M, Deng X,. Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. J Biol Chem 2005; 280: 10781-9.
    • (2005) J Biol Chem , vol.280 , pp. 10781-10789
    • Xin, M.1    Deng, X.2
  • 37
    • 0035873953 scopus 로고    scopus 로고
    • Tumor suppressor and anti-inflammatory actions of PPARγamma agonists are mediated via upregulation of PTEN
    • Patel L, Pass I, Coxon P, et al. Tumor suppressor and anti-inflammatory actions of PPARγamma agonists are mediated via upregulation of PTEN. Curr Biol 2001; 11: 764-8.
    • (2001) Curr Biol , vol.11 , pp. 764-768
    • Patel, L.1    Pass, I.2    Coxon, P.3
  • 38
    • 75649133232 scopus 로고    scopus 로고
    • Alpha-eleostearic acid suppresses proliferation of MCF-7 breast cancer cells via activation of PPARγamma and inhibition of ERK 1/2
    • Moon HS, Guo DD, Lee HG, et al. Alpha-eleostearic acid suppresses proliferation of MCF-7 breast cancer cells via activation of PPARγamma and inhibition of ERK 1/2. Cancer Sci 2010; 101: 396-402.
    • (2010) Cancer Sci , vol.101 , pp. 396-402
    • Moon, H.S.1    Guo, D.D.2    Lee, H.G.3
  • 39
    • 0036714806 scopus 로고    scopus 로고
    • Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland
    • Li G, Robinson GW, Lesche R, et al. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 2002; 129: 4159-70.
    • (2002) Development , vol.129 , pp. 4159-4170
    • Li, G.1    Robinson, G.W.2    Lesche, R.3
  • 40
    • 0033152120 scopus 로고    scopus 로고
    • Gain of Bcl-2 is more potent than bax loss in regulating mammary epithelial cell survival in vivo
    • Schorr K, Li M, Bar-Peled U, et al. Gain of Bcl-2 is more potent than bax loss in regulating mammary epithelial cell survival in vivo. Cancer Res 1999; 59: 2541-5.
    • (1999) Cancer Res , vol.59 , pp. 2541-2545
    • Schorr, K.1    Li, M.2    Bar-Peled, U.3
  • 41
    • 0033577766 scopus 로고    scopus 로고
    • Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: Reduction in protective apoptotic response at the preneoplastic stage
    • Shibata MA, Liu ML, Knudson MC, et al. Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. EMBO J 1999; 18: 2692-701.
    • (1999) EMBO J , vol.18 , pp. 2692-2701
    • Shibata, M.A.1    Liu, M.L.2    Knudson, M.C.3
  • 42
    • 67649220699 scopus 로고    scopus 로고
    • Mammary involution and breast cancer risk: Transgenic models and clinical studies
    • Radisky DC, Hartmann LC,. Mammary involution and breast cancer risk: transgenic models and clinical studies. J Mammary Gland Biol Neoplasia 2009; 14: 181-91.
    • (2009) J Mammary Gland Biol Neoplasia , vol.14 , pp. 181-191
    • Radisky, D.C.1    Hartmann, L.C.2
  • 43
    • 0037089506 scopus 로고    scopus 로고
    • Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer
    • Kundu N, Fulton AM,. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 2002; 62: 2343-6.
    • (2002) Cancer Res , vol.62 , pp. 2343-2346
    • Kundu, N.1    Fulton, A.M.2
  • 44
    • 79952706985 scopus 로고    scopus 로고
    • Transforming growth factor-beta and the hallmarks of cancer
    • Tian M, Neil JR, Schiemann WP,. Transforming growth factor-beta and the hallmarks of cancer. Cell Signal 2011; 23: 951-62.
    • (2011) Cell Signal , vol.23 , pp. 951-962
    • Tian, M.1    Neil, J.R.2    Schiemann, W.P.3
  • 45
    • 82955212867 scopus 로고    scopus 로고
    • COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin
    • Holmes MD, Chen WY, Schnitt SJ, et al. COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat 2011; 130: 657-62.
    • (2011) Breast Cancer Res Treat , vol.130 , pp. 657-662
    • Holmes, M.D.1    Chen, W.Y.2    Schnitt, S.J.3
  • 46
    • 33746906228 scopus 로고    scopus 로고
    • Immune enhancement and anti-tumour activity of IL-23
    • Hao JS, Shan BE,. Immune enhancement and anti-tumour activity of IL-23. Cancer Immunol Immunother CII 2006; 55: 1426-31.
    • (2006) Cancer Immunol Immunother CII , vol.55 , pp. 1426-1431
    • Hao, J.S.1    Shan, B.E.2
  • 47
    • 0035052916 scopus 로고    scopus 로고
    • Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1
    • Wang C, Fu M, D'Amico M, et al. Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. Mol Cell Biol 2001; 21: 3057-70.
    • (2001) Mol Cell Biol , vol.21 , pp. 3057-3070
    • Wang, C.1    Fu, M.2    D'Amico, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.